Wells Fargo analyst Stephen Baxter raised the firm’s price target on Cencora (COR) to $354 from $337 and keeps an Overweight rating on the shares. The firm views Q3 2025 results, particularly the earnings growth acceleration in U.S. Healthcare, as encouraging. Wells sees commentary on 2026 as pragmatic and typical for Cencora and doesn’t believe the company has line of sight to any discrete driver of moderation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR: